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allele A in the study group was 8%, in the control group – 4% (р = 0.1; 
chi-square). The following genotypes distribution was observed in the 
study group: АА – 0.02; AG – 0.13; GG – 0.85. In the control group the 
following genotype distribution was observed: АА – 0.01; AG – 0.05; 
GG – 0.94. Distributions corresponded to Hardy-Weinberg equilibrium.
Conclusion: In our prospective study, we observed tendency to genetic 
predisposition to higher activity of CYP3A5 in women with stillbirth 
compared with matched women with normal pregnancy. The results, 
however, did not reach statistical significance, which may demonstrate 
either lack of real association or insufficient number of subjects recruited. 
The observation needs to be proved or disproved in a larger population.
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Introduction: Venlafaxine, as a substrate of p-glycoprotein, is a 
widely used serotonin-noradrenaline reuptake inhibitor (SNRI). The 
aim of the study is to investigate the influence of ABCB1 G2677T/A, 
C3435T polymorphisms on efficacy of venlafaxine.
Patients (or Materials) and Methods: Patients (n = 52) who met 
the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition-IV criteria for major depressive disorder (MDD) were 
enrolled the study. All patients had affirmed for once a day adminis-
tration of venlafaxine at 8:00 to 9:00 am during the study. Protocol 
visits were completed at baseline, 1st, 2nd, 4th, and 6th weeks. 
The clinical response to venlafaxine was evaluated by psychiatrists 
with 17-item Hamilton Rating Scale for Depression (HAM-D17). 
Blood samples were taken for genotyping at 4th week of the study. 
Genotyping for the ABCB1 gene 3435C> T and G2677T/A polymor-
phisms was performed by PCR/RFLP assays.
Results: Our results showed that there is no correlation between effi-
cacy and tolerability of venlafaxine and ABCB1 G2677T/A, C3435T 
polymorphisms. But carriers of the TT genotype for 3435C> T poly-
morphism and carriers of the TT/TA genotype for G2677T/A poly-
morphism could be tended to be poor responder (Table).
Conclusion: Although our results showed that there is no correlation 
between efficacy of venlafaxine and ABCB1 G2677T/A, C3435T pol-
ymorphisms, we couldn’t reach the sufficient patient number. There is 
need for studies with sufficient patient number and haplotype analysis 
including also ABCB1 C1236T polymorphism in MDD patients.
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Introduction: The promise of personalized care has not always 
translated into improvements in patient care. There are concerns 
among payers that advice for certain genetic tests has been revoked, 
diagnostic tests can be costly, and there is fragmentation of funding 
of care including tests. In addition, pharmaceutical companies are 
seeking high prices for new targeted drugs through designating them 
as orphan drugs. Consequently, there is a need to integrate current 
knowledge about the value of genetic, biomarkers, prognostic tests 
and targeted drug therapies from a health authority perspective to 
provide future guidance.
Patients (or Materials) and Methods: This will be achieved by (1) 
reviewing the current literature regarding personalized medicine; 
(2) appraising key funding, organizational, and health care issues 
that need to be addressed especially from a health authority per-
spective; and (3) suggesting future avenues for all key stakeholder 
groups to enhance future funding and utilization of new personalized 
approaches to improve future patient care. The latter will be achieved 
through an iterative process.
Results: Multiple findings are consolidated under headings. These 
include (1) general considerations incorporating definitions and the 
need for different approaches to progress personalized medicine; (2) 
knowledge about the influence of pharmacogenomics on response 
and toxicity of drug therapies using current examples including cases 
where recommendations have recently been revoked; (3) knowledge 
of the value of biomarker tests to target treatment approaches; (4) 
challenges and concerns including the potentially high cost of tests 
and targeted therapies and current fragmentation of funding; and 
(5) key issues for health care funding bodies to address to enhance 
funding for new diagnostic/prognostic tests as well as new targeted 
therapies. Guidance is given on potential ways forward for all key 
stakeholder groups including reviewing key medical, ethical, legal, 
Table.  HAMD17 scores according to ABCB1 G2677T/A, C3435T 
genotypes.
3435C> T 2677G> T/a
CC-CT TT GG-GT-Ga TT-Ta
n 41 11 41 11
HAMD17, baseline 21.56 ± 0.695 22.45 ± 2.077 21.78 ± 0.737 21.64 ± 1.865
HAMD17,
1st week 14.93 ± 0.851 16.73 ± 2.195 15.34 ± 0.852 15.18 ± 2.252
HAMD17,
2nd week 13.76 ±0.939 15.64 ± 1.820 13.59 ± 0.907 16.27 ± 1.978
HAMD17,
4th week 11.27 ± 0.968 11.54 ± 1.883 11.24 ± 0.931 12.36 ± 2.125
HAMD17,
6th week 9.63 ± 1.11 10.09 ± 2.095 9.54 ± 1.038 10.45 ± 2.577
F = 0.41, P = 0.741 F = 0.672, P = 0.563
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social, economic, and organizational issues that need to be addressed 
as the field of personalized medicine grows. As a result, improve 
patient care in the future.
Conclusion: Personalized medicine has the potential to revolu-
tionize care. However, current challenges and concerns need to be 
addressed to enhance uptake and funding to benefit patients in the 
future. Clinical pharmacologists can play critical role with advising 
authorities on the potential value of new diagnostic and prognostic 
tests as well as new targeted therapies.
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Introduction: The statin lipid-lowering efficacy and safety varies 
widely among patients. This is mainly interpersonal differences can 
be explained by genetic factors. The purpose of this study was to 
investigate the prevalence of allelic variants (polymorphism) of the 
gene SLCO1B1 * 5 (c.521T> C, rs4149056), which encodes a poly-
peptide involved in the removal of statins by the liver into the bile, 
as well as prediction of myopathy in patients who are to the use of 
statins. The frequency of genotypes in SLCO1B1 in the Russian popu-
lation is not known in other European ethnic groups is 8% to 20%.
Patients (or Materials) and Methods: The study is based AGL 
Hospital Road station Yaroslavl OJSC “Russian Railways” GBOU 
VPO Yaroslavl State Medical Academy, Russian Ministry of Health 
in 2012–2013. The study included 377 patients with dyslipidemia 
and systemic atherosclerosis. Of these, 226 men (59.95%) and 151 
women (40.05%); the mean age was 52.58 12.21. All patients under-
went determination of single nucleotide polymorphisms SLCO1B1 * 
5 using reagent “SNP-Express” by real-time PCR thermocycler with 
IQ 5 (firm Bio-Rad).
Results: Identified gene polymorphisms SLCO1B1 * 5: heterozygous 
genotype s.521 vehicle in 106 patients (28.12%) and homozygous 
genotype CC s.521 - in 14 patients (3.71%), which is associated with 
an increased risk of myopathy with statins and the need for correction 
of the maximum dose to be lower compared with the TT genotype 
s.521 (“wild” type.)
Conclusion: The frequency of the heterozygous genotype (s.521TS) 
is 28%, and homozygous genotype (s.521SS) - 4% of patients with 
dyslipidemia and systemic atherosclerosis, which requires a reduc-
tion of the therapeutic dose of statins to one half and one quarter, 
respectively. Thus, the holding of pharmacogenetic testing can be 
useful for your personal selection of the dose of statin to maximize 
the effectiveness and safety of treatment.
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Introduction: CYP2D6 codes for a protein that is vastly involved 
in metabolism of various substances. Different metabolic profiles 
determine the processing of xenobiotics and endobiotics, thereby 
influencing disease risk, therapeutic efficacy and side effects, or toxic-
ity of xenobiotics. The aim of this work was to characterize CYP2D6 
polymorphisms and predict metabolic profiles in the Portuguese 
population.
Patients (or Materials) and Methods: A total of 300 Portuguese 
unrelated adult healthy volunteers were studied. Genetic analysis 
included allelic discrimination and copy number determination 
with TaqMan® probes by real-time PCR and allele duplications of 
CYP2D6*1, CYP2D6*2, CYP2D6*4, and CYP2D6*10 were con-
firmed by long PCR and PCR-RFLP.
Results: The percentages of poor and ultrarapid metabolizers found 
in this Portuguese population were 6.3% and 4.7%, respectively. 
Accordingly, is it estimated that, taking into account the number 
of inhabitants estimated by CENSUS 2011 (10,562,178), there are 
~665,417 poor metabolizers (PM) and 496,422 ultrarapid metaboliz-
ers (UM) in Portugal. The frequency of extensive metabolizers (EM) 
and intermediate metabolizers (IM) is in agreement with previous 
studies.
Conclusion: The allelic frequencies were similar to other stud-
ies of European populations, with some exceptions, such as for 
CYP2D6*10, which is higher in Portuguese population and for 
CYP2D6*6 and duplication of *1 and *2, that present lower frequen-
cies in the present study. After this study, we could evaluate the most 
important CYP2D6 variants in the Portuguese population and pre-
dict metabolic profiles. The data presented here are noteworthy for 
determination of the genetic variability influencing CYP2D6 activity, 
to improve the effectiveness and safety in the xenobiotics exposure, 
working also as a strong tool for clinical practice and development 
of individualized pharmacotherapy.
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Introduction: CYP2C9 is involved in the metabolism of drugs 
such as warfarin, losartan, fluoxetine, and NSAIDs. The frequency 
of CYP2C9*2, allele causing decreased enzyme activity, has been 
reported to be lower in Amerindian and Admixed populations (from 
Cuba, Nicaragua, Ecuador, and Mexico), than in Spanish-Caucasian 
populations.1,2 The aim of this study was to determine CYP2C9 
allele frequencies in 3 Costa Rican ethnic groups and to compare 
the results with frequencies previously reported for Hispanic popu-
lations.
Patients (or Materials) and Methods: The CYP2C9 alleles (*2, *3 and 
*6) were analyzed by real-time-PCR among 375 healthy individuals 
belonging to 3 ethnic groups living in Costa Rica: Amerindians (AM; 
n = 193), Afro-Caribbeans (AC; n = 45) and Costa Rican Mestizo 
population (CRM; n = 137). These frequencies were compared with 
a population of Spaniards (SP n = 327) 2 previously published.
Results: The frequency of CYP2C9*2 was significantly lower in the 
AM (2.8%) and CRM (7.7%) than in the SP group (16%; P < 0.05). 
